摘要
TRIPS协议第39条第3款规定了对药品试验数据的保护义务:不披露和防止不公平的商业使用。考察该条款的谈判历史以及美国、欧盟、加拿大和发展中国家的立法保护模式与司法判例,得出的结论为各国国内立法和判例对这两项义务解释不尽相同。在此基础上进一步分析双边和区域贸易协定中美国和欧盟所采取的策略和贸易措施及其对实施《多哈健康宣言》的影响,并结合实际对我国关于药品试验数据的保护提出建议。
Article 39,paragraph 3 of the TRIPS Agreement provides for the obligations to protect pharmaceutical test data against disclosure and unfair commercial use.From the history of the negotiations of this provision,as well as the legislation and jurisprudence of the United States,European Union,Canada and developing countries,it is concluded that the above national legislation and jurisprudence follow divergent aproaches to the interpretation of these two obligations.The article further analyzes the strategy and measures adopted by the United States and European Union and their impact on the implementation of the Doha Health Declaration.Finally,a few propositions are advanced for the protection of pharmaceutical test data in China.
出处
《武大国际法评论》
CSSCI
2010年第1期125-144,共20页
Wuhan University International Law Review
基金
教育部人文社会科学重点研究基地项目"二十一世纪国际知识产权制度发展中的若干重大法律问题研究"(项目批准号07JJD820163)的阶段性成果
